Profile picture

Professor James Januzzi

Massachusetts General Hospital - Harvard Medical School, Boston (United States of America)
Membership: FESC Member HFA Member
Follow
Biography
James L. Januzzi, MD attended New York Medical College, graduating as the top-ranked student in 1994. He then performed a residency in internal medicine at Brigham and Women’s Hospital, followed by fellowship in cardiology and cardiac ultrasound at Massachusetts General Hospital, where he joined the full time staff in 2000. Presently, Dr. Januzzi is the Hutter Family Professor of Medicine at Harvard Medical School. Dr. Januzzi's research has contributed to the understanding of cardiac biomarker testing, where his studies have set international guideline standards for use in diagnosis, prognosis, and management of patients suffering from heart failure as well as those with acute coronary syndromes. Dr. Januzzi has published hundreds of manuscripts, book chapters and review articles, and has edited six text books. He is an Associate Editor at both JACC and JACC Heart Failure and is a Trustee at the American College of Cardiology.
Logo ESC

Contributor content

Next generation heart failure care: a personalised approach
Session
Next generation heart failure care: a personalised approach
10 May 2026
Clinical Case Management: digital innovation in heart failure practice
Session
Clinical Case Management: digital innovation in heart failure practice
9 May 2026
Contemporary biomarkers for diagnosis, monitoring, and prognosis in heart failure
Session
Contemporary biomarkers for diagnosis, monitoring, and prognosis in heart failure
9 May 2026
Predicting outcomes and mortality in heart failure
Session
Predicting outcomes and mortality in heart failure
31 August 2025
Evolving approaches to diagnosing heart failure
Session
Evolving approaches to diagnosing heart failure
30 August 2025
Controversies in 2021 OMT: should SGLT2i and ARNI now be considered first line treatments in HFrEF?
Session
Controversies in 2021 OMT: should SGLT2i and ARNI now be considered first line treatments in HFrEF?
30 June 2021
Diagnostic and prognostic value of biomarkers in acute heart failure
Session
Diagnostic and prognostic value of biomarkers in acute heart failure
30 June 2021
The potential of new and unusual biomarkers in heart failure
Session
The potential of new and unusual biomarkers in heart failure
27 August 2018
Biomarkers in chronic heart failure
Session
Biomarkers in chronic heart failure
1 May 2017
NT-proBNP: the gold standard biomarker in heart failure
Session
NT-proBNP: the gold standard biomarker in heart failure
29 April 2017

ESC 365 is supported by